Investor deep dive
ImmuPharma targets regulatory approval as follow-up study confirms “outstanding” safety profile of Lupuzor
Analyst sees 'clear rationale' for ImmuPharma to move forward with Lupuzor
Dr Malik says despite not meeting its primary end point in a recent phase III trial, the response rate overall compares well to a number of other pivotal studies and has an excellent safety profile.
Worldwide, there are 5mln people with Lupus, 1.5mln of them in the US, Europe and Japan.
Quick facts: ImmuPharma PLC
Market Cap: £16.26 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE